Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Current Assets (2022 - 2025)

Historic Current Assets for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $732.3 million.

  • NewAmsterdam Pharma's Current Assets rose 6724.63% to $732.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $732.3 million, marking a year-over-year increase of 6724.63%. This contributed to the annual value of $863.4 million for FY2024, which is 14897.21% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma's Current Assets is $732.3 million, which was up 6724.63% from $769.8 million recorded in Q2 2025.
  • NewAmsterdam Pharma's Current Assets' 5-year high stood at $863.4 million during Q4 2024, with a 5-year trough of $346.8 million in Q4 2023.
  • Its 4-year average for Current Assets is $578.2 million, with a median of $472.5 million in 2022.
  • As far as peak fluctuations go, NewAmsterdam Pharma's Current Assets crashed by 2415.0% in 2023, and later surged by 14897.21% in 2024.
  • Over the past 4 years, NewAmsterdam Pharma's Current Assets (Quarter) stood at $457.2 million in 2022, then decreased by 24.15% to $346.8 million in 2023, then surged by 148.97% to $863.4 million in 2024, then dropped by 15.18% to $732.3 million in 2025.
  • Its Current Assets stands at $732.3 million for Q3 2025, versus $769.8 million for Q2 2025 and $817.3 million for Q1 2025.